glp-1 obesity drug updates Scientists rethink delivery to improve dosing, tolerability, and adherence The FDA approved a new
Description
Hinyokika Kiyo (1995) 41(1):515
Subsequently, mice with cardiomyocyte-specific (CM-specific) deletion of Glp1r also showed cardioprotective effects of liraglutide in an in vivo model of MI (22), suggesting that the cardioprotective effects of this agent are derived from actions independent of CMs and/or the GLP-1R
Still, results should be carefully generalized to cases of background kidney dysfunction or when using drugs with narrow therapeutic index." Dr
One flat monthly price: $129/mo covers everything
